#NASH

Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.

The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.

Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.

People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.

Researchers reported significant changes in liver, cardiovascular and diabetes markers.

The regulatory agency requested further data to show whether its benefits outweigh its risks.

Non-alcoholic fatty liver disease can be driven by toxin exposure.

Instead of non-alcoholic fatty liver disease, they suggest calling it metabolic-associated fatty liver disease.

A compound found in veggies such as broccoli, kale and Brussels sprouts may help prevent a liver condition that increases cancer risk.

Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.

Those with NAFLD or NASH and cirrhosis should undergo regular screening.

Gastrointestinal cancers conference emphasizes patient quality of life.

Three fatty liver disease candidates miss the mark for effectiveness or safety.

The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.

Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.

The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.